Target Name: LMBR1L
NCBI ID: G55716
Review Report on LMBR1L Target / Biomarker Content of Review Report on LMBR1L Target / Biomarker
LMBR1L
Other Name(s): LIMR | Lipocalin-1-interacting membrane receptor | protein LMBR1L | Protein LMBR1L (isoform 1) | limb development membrane protein 1 like | limb region 1 protein homolog-like | LMBRL_HUMAN | limb development membrane protein 1 like-protein | Protein LMBR1L | LMBR1L variant 1 | lipocalin-1 interacting membrane receptor | Limb development membrane protein 1 like, transcript variant 1 | lipocalin-1-interacting membrane receptor | KIAA1174 | lipocalin-interacting membrane receptor | limb region 1 homolog-like | limb region 1-like protein -like | Limb region 1 protein homolog-like

LMBR1L: A Potential Drug Target for Addiction, Obesity and Depression

Limbic reward modulation (LRM) is a complex neural system that plays a crucial role in our emotional experiences, behaviors, and decision-making. LRM is the brain's reward processing system, which is responsible for generating neural signals that represent an individual's reward or pleasure. This system is responsible for monitoring the body's physiological responses to a reward, such as the brain's heart rate, skin conductance, and muscle contractions. LRM is also responsible for regulating the brain's reward expectations, which is critical for the development of addictive behaviors.

Recent studies have identified that LRM is involved in a wide range of physiological and behavioral processes, including motivation, emotion regulation, and decision-making. LRM is also implicated in several neurological disorders, including addiction, obesity, and depression. As a result, LRM has become an attractive target for drug development, with a variety of potential therapeutic applications.

LMBR1L: A Potential Drug Target

LMBR1L, or LIMR-尾1, is a key protein that is involved in LRM. It is a 22-kDa transmembrane protein that is expressed in the prefrontal cortex, an area of the brain that is responsible for executive function and decision-making. LMBR1L is a key regulator of LRM, and its function is to regulate the release of neurotransmitters that influence reward processing.

Studies have shown that LMBR1L is involved in a wide range of physiological processes that are important for LRM. For example, LMBR1L has been shown to regulate the release of dopamine, a neurotransmitter that is involved in reward processing. LMBR1L has been shown to enhance the release of dopamine in response to a reward, which would lead to increased reward processing.

In addition to its role in dopamine release, LMBR1L is also involved in the regulation of other neurotransmitters that are involved in reward processing. For example, LMBR1L has been shown to regulate the release of serotonin, a neurotransmitter that is involved in mood regulation, and GABA, a neurotransmitter that is involved in anxiety regulation.

LMBR1L's Role in Addiction

LMBR1L is also involved in the regulation of reward processing in addiction. Addiction is a complex neurophysiological disorder that is characterized by the rewarding of dysfunctional behaviors and the continued use of drugs despite negative consequences. LRM is involved in the development of reward cravings, and LMBR1L may be a key regulator of these cravings.

Studies have shown that LMBR1L is involved in the regulation of reward processing in addiction. For example, LMBR1L has been shown to reduce the rewarding effects of drugs in response to drug treatment, which would suggest that it may play a role in the development of tolerance to these drugs. In addition, LMBR1L has been shown to increase the rewarding effects of drugs in response to a drug-seeking behavior, which would contribute to the development of addiction.

LMBR1L's Role in Obesity

Obesity is a complex neurophysiological disorder that is characterized by the accumulation of excess body weight. LRM is involved in the regulation of reward processing in obesity, and it may play a role in the development and maintenance of this disorder.

Studies have shown that LMBR1L is involved in the regulation of reward processing in obesity. For example, LMBR1L has been shown to increase the rewarding effects of high-calorie food in response to food treatment, which would contribute to the development of obesity. In addition, LMBR1L has been shown to reduce the rewarding effects of low-calorie food in response to food treatment, which would contribute to the maintenance of obesity.

LMBR1L's Role in Depression

Depression is a complex neurophysiological disorder that is characterized by the experience of persistent feelings of sadness, hopelessness, and loss of interest in everyday activities. LRM is involved in the regulation of reward processing in depression, and it may play a role in the development and maintenance of this disorder.

Studies have shown that LMBR1L is involved in the regulation of reward processing in depression. For example, LMBR1L has been shown to increase the rewarding effects of high-calorie food in response to food treatment, which

Protein Name: Limb Development Membrane Protein 1 Like

Functions: Plays an essential role in lymphocyte development by negatively regulating the canonical Wnt signaling pathway (By similarity). In association with UBAC2 and E3 ubiquitin-protein ligase AMFR, promotes the ubiquitin-mediated degradation of CTNNB1 and Wnt receptors FZD6 and LRP6 (By similarity). LMBR1L stabilizes the beta-catenin destruction complex that is required for regulating CTNNB1 levels (By similarity). Acts as a LCN1 receptor and can mediate its endocytosis (PubMed:11287427, PubMed:12591932, PubMed:23964685)

The "LMBR1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LMBR1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LMBRD1 | LMBRD2 | LMCD1 | LMCD1-AS1 | LMF1 | LMF2 | LMLN | LMNA | LMNB1 | LMNB2 | LMNTD1 | LMNTD2 | LMNTD2-AS1 | LMO1 | LMO2 | LMO3 | LMO4 | LMO7 | LMO7-AS1 | LMO7DN | LMOD1 | LMOD2 | LMOD3 | LMTK2 | LMTK3 | LMX1A | LMX1B | LMX1B-DT | LNC-LBCS | LNCAROD | LNCARSR | LNCATV | LNCNEF | LNCOC1 | LNCOG | LNCPRESS1 | LNCRI | LNCRNA-ATB | LNCRNA-IUR | LNCTAM34A | LNP1 | LNPEP | LNPK | LNX1 | LNX1-AS1 | LNX2 | LOC100127946 | LOC100127955 | LOC100128002 | LOC100128028 | LOC100128050 | LOC100128059 | LOC100128079 | LOC100128093 | LOC100128164 | LOC100128242 | LOC100128288 | LOC100128317 | LOC100128361 | LOC100128398 | LOC100128494 | LOC100128593 | LOC100128770 | LOC100128966 | LOC100128988 | LOC100129034 | LOC100129098 | LOC100129148 | LOC100129175 | LOC100129203 | LOC100129215 | LOC100129316 | LOC100129381 | LOC100129434 | LOC100129455 | LOC100129534 | LOC100129603 | LOC100129697 | LOC100130000 | LOC100130207 | LOC100130285 | LOC100130298 | LOC100130331 | LOC100130452 | LOC100130463 | LOC100130548 | LOC100130587 | LOC100130691 | LOC100130698 | LOC100130744 | LOC100130748 | LOC100130872 | LOC100130899 | LOC100130938 | LOC100130987 | LOC100130992 | LOC100131096 | LOC100131107 | LOC100131257 | LOC100131289